Description: <p><b>Annona atemoya Seed Extract</b> - Atemoya Seed Extract</p>
<p><b>Abbreviation:</b> AAS, EEAA for ethanol extract</p>
<p><b>Type:</b> Botanical seed extract / acetogenin-rich plant product</p>
<p><b>Source:</b> Seeds of Annona atemoya.</p>
<p><b>Active Constituents:</b> Annona atemoya seeds contain annonaceous acetogenins including bullatacin and related cytotoxic acetogenins, together with other phytochemical constituents.</p>
<p><b>Function:</b> Annona atemoya seed extract exhibits anti-angiogenic and antiproliferative activity in experimental models. Its effects include inhibition of endothelial-cell proliferation, migration, and tube formation and suppression of hypoxia-responsive angiogenic signaling.</p>
<p><b>Cancer:</b> Preclinical studies show anti-angiogenic activity in vitro and in vivo. Ethanol extract of Annona atemoya seeds suppresses tumor-associated angiogenesis and reduces HIF-1α, HIF-2α, and VEGF expression under hypoxic conditions. Acetogenins such as bullatacin may also contribute direct cytotoxic and pro-apoptotic effects. Clinical anticancer efficacy has not been established.</p>
<p><b>Annona atemoya Seed Extract</b> — A botanical extract prepared from the seeds of <i>Annona atemoya</i>, a hybrid of <i>Annona squamosa</i> and <i>Annona cherimola</i>. It is an acetogenin-rich botanical product with experimental anti-angiogenic and cytotoxic activity. Standard abbreviations are AAS for <i>Annona atemoya</i> seed material and EEAA for ethanol extract of <i>Annona atemoya</i> seeds. The seeds contain particularly high concentrations and diversity of annonaceous acetogenins, including bullatacin, bullatanocin, squamocin derivatives, atemoyacins, annotemoyins and related compounds. Unlike the edible fruit pulp, the seeds should not be regarded as a conventional food ingredient because acetogenin-rich seed extracts have substantial experimental neurotoxicity.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Anti-angiogenesis through suppression of hypoxia-responsive HIF-1α, HIF-2α and VEGF signaling, reducing endothelial proliferation, migration and tube formation.</li>
<li>Mitochondrial electron-transport inhibition by annonaceous acetogenins, particularly inhibition of respiratory complex I, causing severe energetic stress and contributing to cytotoxicity.</li>
<li>Direct antiproliferative and cytotoxic activity of seed acetogenins against multiple cancer-cell lines.</li>
<li>Induction of apoptosis by acetogenin constituents such as bullatacin, associated in hepatoma models with reduced intracellular cAMP and cGMP.</li>
<li>Suppression of multidrug resistance by specific <i>A. atemoya</i> acetogenins through inhibition of P-glycoprotein activity (compound-dependent).</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human pharmacokinetics, systemic bioavailability, therapeutic dosing and standardized extract composition have not been established. Acetogenins are lipophilic constituents, and extract composition varies substantially with solvent, cultivar and preparation. There is no validated human exposure range corresponding to the concentrations producing anticancer effects experimentally.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer evidence derives from purified acetogenins, cultured cells, endothelial assays and animal angiogenesis or xenograft models. Whether active concentrations can be achieved safely in humans is unknown. This is particularly important because mitochondrial complex-I inhibition is not cancer-specific and acetogenin-rich <i>Annona</i> seed extracts demonstrate potent neuronal toxicity experimentally.</p>
<p><b>Clinical evidence status:</b> Preclinical only. Anti-angiogenic effects have been demonstrated in vitro and in animal models, and isolated seed acetogenins have shown strong cytotoxicity and some xenograft activity. No established human anticancer efficacy, validated clinical dosing regimen or approved therapeutic use was identified. Safety is a major translational limitation, particularly potential acetogenin-associated neurotoxicity.</p>
<h3>Mechanistic Effects of Annona atemoya Seed Extract</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HIF-1α / HIF-2α / VEGF angiogenesis</td>
<td>↓ HIF-1α<br>↓ HIF-2α<br>↓ VEGF</td>
<td>↓ endothelial angiogenic responses</td>
<td>Anti-angiogenesis</td>
<td>EEAA suppresses hypoxia-responsive HIF and VEGF expression and inhibits tumor-associated angiogenesis in experimental models.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial complex I and oxidative phosphorylation</td>
<td>↓ complex I<br>↓ mitochondrial ATP production</td>
<td>↓ complex I<br>↓ mitochondrial ATP production</td>
<td>Energetic collapse and cytotoxicity</td>
<td>Characteristic mechanism of annonaceous acetogenins abundant in the seeds. This mechanism is not tumor-specific and is also a major mechanistic basis for neurotoxicity.</td>
</tr>
<tr>
<td>3</td>
<td>Cancer-cell proliferation and viability</td>
<td>↓ proliferation<br>↓ viability</td>
<td>↓ viability (high concentration or susceptible cells)</td>
<td>Direct cytotoxicity</td>
<td>Multiple isolated seed acetogenins show potent cytotoxicity against HepG2, Hep 2.2.15, KB, CCM2 and CEM cells. Activity varies substantially among individual acetogenins.</td>
</tr>
<tr>
<td>4</td>
<td>Apoptosis</td>
<td>↑ apoptosis</td>
<td>Potential ↑ cell death (context-dependent)</td>
<td>Programmed cell death</td>
<td>Bullatacin and related acetogenins contribute pro-apoptotic activity; the evidence is considerably stronger for isolated constituents than for standardized whole-seed extract.</td>
</tr>
<tr>
<td>5</td>
<td>cAMP / cGMP signaling</td>
<td>↓ cAMP<br>↓ cGMP</td>
<td>Not established</td>
<td>Apoptosis-associated signaling disruption</td>
<td>Reported for bullatacin in hepatoma cells rather than established as a universal effect of crude seed extract.</td>
</tr>
<tr>
<td>6</td>
<td>Endothelial proliferation</td>
<td>Indirect ↓ tumor vascular support</td>
<td>↓ endothelial proliferation</td>
<td>Reduced formation of tumor vasculature</td>
<td>Observed directly with EEAA in HUVEC-based angiogenesis assays.</td>
</tr>
<tr>
<td>7</td>
<td>Endothelial migration and tube formation</td>
<td>Indirect ↓ angiogenesis</td>
<td>↓ migration<br>↓ tube formation</td>
<td>Impaired vascular organization</td>
<td>Supports the anti-angiogenic action independently of direct tumor-cell cytotoxicity.</td>
</tr>
<tr>
<td>8</td>
<td>P-glycoprotein multidrug resistance</td>
<td>↓ P-glycoprotein activity (compound-dependent)</td>
<td>Not established</td>
<td>Chemosensitization</td>
<td>An acetogenin designated 89-2 isolated from <i>A. atemoya</i> showed activity against multidrug-resistant KBv200 cells and inhibition of P-glycoprotein. This should not be generalized to all seed extracts.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>Potential therapeutic window not established</td>
<td>↓ neuronal viability with acetogenin-rich seed extract</td>
<td>Major safety and exposure limitation</td>
<td>No human anticancer efficacy or PK has been established. <i>A. atemoya</i> seed ethyl-acetate extract produced pronounced toxicity in human neuronal LUHMES cells at very low experimental concentrations; chronic mitochondrial complex-I inhibition is a significant safety concern.</td>
</tr>
</tbody>
</table>